

Generalized Anxiety Disorder (GAD) - Pipeline Insight, 2020

<https://marketpublishers.com/r/GE1F67F67D01EN.html>

Date: October 2020

Pages: 65

Price: US\$ 1,500.00 (Single User License)

ID: GE1F67F67D01EN

Abstracts

This report can be delivered to the clients within 24 - 48 Hours

DelveInsight's, "Generalized Anxiety Disorder (GAD) – Pipeline Insight, 2020," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Generalized Anxiety Disorder Understanding

Generalized Anxiety Disorder (GAD): Overview

Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. People with generalized anxiety disorder (GAD) display excessive anxiety or worry, most days for at least 6 months, about a number of things such as personal health, work, social interactions,

and everyday routine life circumstances. The fear and anxiety can cause significant problems in areas of their life, such as social interactions, school, and work.

Symptoms

Generalized anxiety disorder symptoms include:

Feeling restless, wound-up, or on-edge

Being easily fatigued

Having difficulty concentrating; mind going blank

Being irritable

Having muscle tension

Difficulty controlling feelings of worry

Having sleep problems, such as difficulty falling or staying asleep, restlessness, or unsatisfying sleep

Diagnosis

Generalized Anxiety Disorder is diagnosed with a mental health screening that a primary care provider can perform. They will ask questions about symptoms and how long the patient have had them. They can refer the patients to a mental health specialist, such as a psychologist or psychiatrist. If the primary care provider suspects that a medical condition or substance abuse problem is causing anxiety, they may perform more tests. These may include:

blood tests, to check hormone levels that may indicate a thyroid disorder

urine tests, to check for substance abuse

gastric reflux tests, such as an X-ray of your digestive system or an endoscopy procedure to look at your esophagus, to check for GERD

X-rays and stress tests, to check for heart conditions

Treatment

Treatment for Generalized Anxiety Disorder most often includes a combination of medication and cognitive behavioral therapy.

Cognitive behavioral therapy: People being treated for anxiety disorders often take part in this type of therapy, in which they learn to recognize and change thought patterns and behaviors that lead to anxious feelings.

Medications: These aren't a cure, but they can help ease symptoms. The drugs most often used to treat GAD in the short term (since they can be addictive, are sedating, and can interfere with memory and attention) are from a group of drugs called benzodiazepines.

Common benzodiazepines include alprazolam (Xanax), clordiazepoxide Hcl (Librium), diazepam (Valium), and lorazepam (Ativan).

Generalized Anxiety Disorder Emerging Drugs Chapters

This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Generalized Anxiety Disorder Emerging Drugs

Vilazodone: AbbVie; Allergan; m8 Pharmaceuticals

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT_{1A} receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). Vilazodone has been speculated to have three potential benefits including faster onset of action, greater efficacy, and better tolerability owing to its SPARI properties.

Further product details are provided in the report.

Generalized Anxiety Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Generalized Anxiety Disorder

There are approx. 8+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AbbVie, Allergan, m8 Pharmaceuticals etc.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Peptides

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Generalized Anxiety Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.

Generalized Anxiety Disorder Report Insights

Generalized Anxiety Disorder Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Generalized Anxiety Disorder Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Generalized Anxiety Disorder drugs?

How many Generalized Anxiety Disorder drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Generalized Anxiety Disorder and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AbbVie

Allergan

m8 Pharmaceuticals

OWP Pharmaceuticals

Key Products

Vilazodone

Duloxetine oral suspension

Contents

Introduction

Executive Summary

Generalized Anxiety Disorder: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Generalized Anxiety Disorder – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Generalized Anxiety Disorder companies' collaborations, Licensing, Acquisition -Deal Value Trends

Generalized Anxiety Disorder Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Vilazodone: AbbVie

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Duloxetine oral suspension: OWP Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Generalized Anxiety Disorder Key Companies

Generalized Anxiety Disorder Key Products

Generalized Anxiety Disorder- Unmet Needs

Generalized Anxiety Disorder- Market Drivers and Barriers

Generalized Anxiety Disorder- Future Perspectives and Conclusion

Generalized Anxiety Disorder Analyst Views

Generalized Anxiety Disorder Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Generalized Anxiety Disorder

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Generalized Anxiety Disorder

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Generalized Anxiety Disorder (GAD) - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/GE1F67F67D01EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE1F67F67D01EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970